搜尋結果
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for ...
Bastillepost· 4 日前ImmunityBio, Inc. ( NASDAQ: IBRX ), an immunotherapy company, today announced that the U.S. ...
How Predictive Healthcare Can Improve African American Women’s Experience
Forbes· 6 日前Center for Health Statistics, in the United States, black women represent 14.4% of the female ...